A US life sciences real estate investor has set out big ambitions for its entry to the UK market, eyeing a new fund that could bring in as much as $2bn (£1.4bn) in the coming months.
Adam Sichol,
Thank you for reading EG
Want to read more? Enjoy a story a week for FREE for one month.
